← Back to headlines
Argenx's Vyvgart Meets Key Endpoints in Autoimmune Myositis Trial
Argenx has made progress as its drug, Vyvgart, successfully met key trial endpoints for the treatment of autoimmune myositis.
17 Aug, 08:28 — 17 Aug, 08:28
Sources
Showing 1 of 1 sources
